June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Complete and systematic evaluation of ocular involvement in systemic lupus erythematosus: first global study.
Author Affiliations & Notes
  • Alvaro Olate-Perez
    LEAOS, Faculty of Medicine/Clinical Hospital, Universidad de Chile, Santiago de Chile, Chile
  • Fabian Vega-Tapia
    LEAOS, Faculty of Medicine/Clinical Hospital, Universidad de Chile, Santiago de Chile, Chile
  • Loreto Cuitino
    LEAOS, Faculty of Medicine/Clinical Hospital, Universidad de Chile, Santiago de Chile, Chile
  • Rodrigo A Valenzuela
    Department of Health Sciences, Universidad de Aysen, Coyhaique, Aysén, Chile
    LEAOS, Faculty of Medicine/Clinical Hospital, Universidad de Chile, Santiago de Chile, Chile
  • Felipe Rojas
    LEAOS, Faculty of Medicine/Clinical Hospital, Universidad de Chile, Santiago de Chile, Chile
  • Nathaly Elizalde
    LEAOS, Faculty of Medicine/Clinical Hospital, Universidad de Chile, Santiago de Chile, Chile
  • Alvaro Rodriguez
    LEAOS, Faculty of Medicine/Clinical Hospital, Universidad de Chile, Santiago de Chile, Chile
  • Oscar Neira
    Rheumatology, Hospital Del Salvador, Santiago, Chile
  • Angela Rivera
    Rheumatology, Hospital Clinico Felix Bulnes Cerda, Santiago, Chile
  • Maria Ines Dominguez
    Rheumatology Unit, Hospital San Juan de Dios, Universidad de Chile, Santiago de Chile, Chile
  • Cecilia Trejo
    Rheumatology Unit, Hospital San Juan de Dios, Universidad de Chile, Santiago de Chile, Chile
  • Annelise Goecke
    Rheumatology, Hospital Clinico de la Universidad de Chile Jose Joaquin Aguirre, Santiago, Chile
  • Catherine A Cukras
    Division of Epidemiology and Clinical Applications, National Eye Institute, Bethesda, Maryland, United States
  • Carolina Llanos
    Clinical Immunology and Rheumatology, Hospital Clinico UC, Santiago, Chile
  • Cristhian A Urzua
    LEAOS, Faculty of Medicine/Clinical Hospital, Universidad de Chile, Santiago de Chile, Chile
    Faculty of Medicine, Universidad del Desarrollo, Clinica Alemana de Santiago SA, Santiago, Chile
  • Footnotes
    Commercial Relationships   Alvaro Olate-Perez None; Fabian Vega-Tapia None; Loreto Cuitino None; Rodrigo Valenzuela None; Felipe Rojas None; Nathaly Elizalde None; Alvaro Rodriguez None; Oscar Neira None; Angela Rivera None; Maria Dominguez None; Cecilia Trejo None; Annelise Goecke None; Catherine Cukras None; Carolina Llanos None; Cristhian Urzua None
  • Footnotes
    Support  ANID FONIS SA19I0211
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3741. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alvaro Olate-Perez, Fabian Vega-Tapia, Loreto Cuitino, Rodrigo A Valenzuela, Felipe Rojas, Nathaly Elizalde, Alvaro Rodriguez, Oscar Neira, Angela Rivera, Maria Ines Dominguez, Cecilia Trejo, Annelise Goecke, Catherine A Cukras, Carolina Llanos, Cristhian A Urzua; Complete and systematic evaluation of ocular involvement in systemic lupus erythematosus: first global study.. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3741.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine frequency/severity of ocular involvement and quality of life in systemic lupus erythematosus (SLE).

Methods : Multicentric cross-sectional study in patients with SLE from 5 centers, in which rheumatological and ophthalmological evaluation was performed. The presence of ocular manifestations was determined by: biomicroscopy/fundoscopy, campimetry, autofluorescence, and optical coherence tomography (OCT). Severity was assessed by applying: OSDI survey, Sicca/Oxford ocular staining scores, Cukras and RCOphth criteria for hydroxychloroquine (HCQ) toxicity and, measuring vascular density (VD) by OCT-Angiography and HCQ plasmatic levels (PL). The quality of life was assessed using NEI-VFQ25 questionnaire.

Results : 119 SLE patients (111 women; mean age: 40 years (+/-13)) were recruited. The most frequent ophthalmological manifestation was dry eye (68.1%). 13.46% of patients previously treated or in treatment with HCQ presented toxicity criteria. There were statistically significant differences (p<0.05) in the duration of HCQ treatment between the group with and without toxicity (8.4 and 5.5 years, respectively), in the cumulative dose (749,000 versus 478,200mg), in superficial (0.36 versus 0.41) and deep (0.33 versus 0.37) VD. No significant differences were found in HCQ-PL. The worst evaluated element in quality of life was general health.

Conclusions : First global study to fully and systematically evaluate ocular involvement in SLE. International data were corroborated (frequency of dry eye and HCQ time/dose relationship with toxicity). These and new findings (decreased VD) may be applied for future protocols.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×